NSCLC or STS with NTRK fusions
Oncology · 2024–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| larotrectinib Treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) or soft tissue sarcoma (STS) harbouring neurotrophic tropomyosin… | Mar 2024 | Recommended with restriction | input received Lung Foundation Australia · Medical Oncology Group |
Who spoke
Lung Foundation Australia · Medical Oncology Group
What the PBS pays
$2M in government benefit over 2024–25, across 271 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| larotrectinib | $2.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.